The phase 3 TETON-2 ( NCT05255991) clinical trial assessed inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...

Please provide your email address to receive an email when new articles are posted on . The most impaired lung function trajectories included rapid decline. Researchers found a link between rapidly ...

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...